Micropulse laser trabeculoplasty for uncontrolled open angle glaucoma in Peruvian patients

Trabeculoplastia a laser Micropulso para glaucoma de ângulo aberto não controlado em pacientes peruanos

ABSTRACT

Objective: We describe the pressure lowering effect of micropulse laser trabeculoplasty (MLT) in patients with uncontrolled open angle glaucoma (OAG). Design: Retrospective case series. Methods: We retrospective reviewed 30 eyes with Open angle Glaucoma (OAG) at the Vista Clinic in Lima, Peru. A single session of MLT treatment was delivered using a 532 nm Frequency doubled Nd. YAG laser to 360º of the trabecular meshwork with a power of 1000 mW, 25 % of duty cycle, and 300 ms. of exposure. The intraocular pressure (IOP) was measured at baseline and at 1 day, 1 week, 3, 6 months post-treatment and were followed up for one last control. Results: The mean baseline IOP was 15.6 mmHg and in the last control was12.8 mmHg, mean follow up time of 19 months (+/- 10 SD). The mean reduction of IOP in the first day was 1.6 mmHg (± 2.6 SD) and 1.2 mmHg (± 3.3 SD) in the last follow up. The mean percentage of IOP reduction was 17.9% and 7 eyes (40%) had IOP reduction greater than 20%. No statistical difference in relation to demographics characteristics of the patients. The greatest reduction was achieved in the first day with a median of 2.00 (P 0.001). A tendency to achieve higher reduction of IOP in patients with higher baseline IOP was found, but was not statistical significant. No adverse reactions occurred. Conclusions: Micropulse laser trabeculoplasty can temporarily be effective in reducing the IOP in some patients with uncontrolled Open angle glaucoma and appears to be safe.

Keywords: Glaucoma, open-angle; Trabeculectomy/methods; Lasers, semiconductor/therapeutic use

RESUMO

Objetivo: Descrevemos o efeito redutor de pressão da trabeculoplastia com laser de micropulso (MLT) em pacientes com glaucoma de ângulo aberto (OAG) descontrolado. Design: Série de casos retrospectiva. Métodos: Foram revisados retrospectivamente 30 olhos com glaucoma de ângulo aberto (OAG) na Clínica Vista em Lima, Peru. Uma única sessão de tratamento com MLT foi administrada usando uma Nd de frequência duplicada de 532 nm. Laser YAG a 360 º da malha trabecular com uma potência de 1000 mW, 25% do ciclo de trabalho e 300 ms. de exposição. A pressão intra-ocular (PIO) foi medida no início e em 1 dia, 1 semana, 3, 6 meses após o tratamento e foram seguidos por um último controle. Resultados: A média da PIO basal foi de 15,6 mmHg e no último controle foi de 12,8 mmHg, com tempo médio de seguimento de 19 meses (+/- 10 DP). A redução média da PIO no primeiro dia foi de 1,6 mmHg (± 2,6 DP) e 1,2 mmHg (± 3,3 DP) no último seguimento. A porcentagem média de redução da PIO foi de 17,9% e 7 olhos (40%) tiveram redução da PIO superior a 20%. Nenhuma diferença estatística em relação às características demográficas dos pacientes. A maior redução foi obtida no primeiro dia com mediana de 2,00 (P 0,001). A tendência de atingir uma redução maior da PIO em pacientes com PIO basal mais alta foi encontrada, mas não foi estatisticamente significativa. Nenhuma reação adversa ocorreu. Conclusões: A trabeculoplastia a laser Micropulse pode ser temporariamente eficaz na redução da PIO em alguns pacientes com glaucoma de ângulo aberto descontrolado e parece ser segura.

Descritores: Glaucoma de ângulo aberto; Trabeculectomia/métodos; Lasers semicondutores/uso terapêutico

INTRODUCTION

Glaucoma is the second leading cause of blindness worldwide and the leading cause of irreversible blindness, accounting for 8 % of all blindness, affecting an estimated 3.12 million blind people in the world.⁽¹⁾ The World Heatlh Organization (WHO) estimated that 12.3 % of blindness was cause by glaucoma in 2002 .⁽²⁾ There will be 79.6 million with glaucoma by 2020, and of these, 74% will have Open angle glaucoma (OAG). Women will comprise 55% of OAG, 70% of angle closure glaucoma (ACG), and 59% of all glaucoma in 2020. Asians will represent 47% of those with glaucoma and 87% of those with ACG. Bilateral blindness will be present to 5.9 and 5.3 million people in 2020, respectively .⁽³⁾ The prevalence of OAG in hispanic subjects was 1.97% (CI 95%), increasing from 0.50% at the age of 41 - 49 years to 12.63% at the age of 80 years.⁽⁴⁾ In Peru the prevalence was 2% (CI 95%).⁽⁵⁾

The main aim of the treatment is to lower the intra ocular pressure (IOP) in order to stop the retinal nerve fiber layer damage and visual field loss. Topical antiglaucoma medications are used before surgery since this last one is related to some complications, despite his efficiency to lower the IOP. The use of laser in the trabeculum was initially described by Wise and Witter in 1979 with the Argon Laser trabeculoplasty (ALT),⁽⁶⁾ and then in 1995 Latina and Park begin to use the Selective Laser trabeculoplasty (SLT).^(7,8) Since then they become widely use for the treatment of OAG, and demonstrated to have similar efficacy to lower the IOP in comparison to topical medications avoiding their side effects.⁽⁹⁾ Other Several studies demonstrated the same efficacy between these two procedures, however SLT has the advantage that it does not leave a noticeable scar on the trabeculum and is repeatable .^(10-16)

More recently, Micropulse laser trabeculoplasty (MLT) has been introduced, and its effects were compared with ALT,⁽¹⁷⁾ despite the few data reported, it showed promising results.^(18-20) This technology use a dutycycle algorithm that delivers subthreshold treatment to ocular tissues without scar formation, making it safe to apply the laser even directly over the fovea and its widely use for the treatment of several maculopathies.^(21-23) It minimizes time in which laser induced heat can spread to adjacent tissues resulting in absence of collateral damage with an induced biological response to the trabecular meshwork that decrease the IOP ^(24-27) and like SLT it doesn’t damage the trabeculum but its efficiency it’s still on debate.

We report on the pressure lowering effect of micropulse laser trabeculoplasty (MLT) in patients with uncontrolled open angle glaucoma of Peruvian eyes in Lima, Peru.

METHODS

Study design

This study is a retrospective chart review of patients who had undergone micropulse laser trabeculoplasty at the Vista Clinic, Lima, Peru. 32 MLT patients were treated between august and december 2014.

Eligibility and exclusion criteria

The study complied with the Declaration of Helsinki. The ethics committee of San Marcos University approved the study, and written informed consent was obtained from the patients before the procedure. Data abstracted from medical records was anonymized and approved by the ethics committee.

We analyze the pressure lowering effect and safety of the procedure and compared to vari¬ous criteria such as age, sex, baseline IOP, and previous surgery on the outcome. Complications such as hipotony, loss of vision, IOP spikes, and anterior uveitis were also evaluated

The inclusion criteria included those with more than 40 years of age that had uncontrolled OAG (including pseudoexfoliation and pigmentary glaucoma as long as angles were open) that was defined as a persistently high IOP (or failing to achieve target IOP) or progression of visual field/retinal nerve fiber layer loss that were with medical therapy (application of one or a combi¬nation of two to four topical medications and/or with oral hypotensive medical treatment) and/or had previous glaucoma surgery. Exclusion criteria included failure to obtain consent, patients with poor access to the angle on gonioscopy (two or more quadrants with iridotrabecular contact), patient who received prior laser trabeculoplasty, laser iridotomy, con¬comitant infection or inflammation, and infirmity sufficient to prevent adequate application of the laser.

Subjects, follow up and measure outcome

The procedure was explained to the patients, and the consent was obtained in writing. Patients were evaluated at 1 day, 1 week, 1 month, 3 months, 6 months, and one last follow up. At each visit, anterior segment examination, best corrected visual acuity and IOP measurements were performed. The IOP was measured by the Goldmann applanation tonometry (AT900, Haag‐Streit, Köniz, Switzerland). The definition of MLT success on the other hand is defined as an IOP reduction of > 20% after MLT.

Laser technique

We did MLT with the frecuency doubled Nd. YAG laser (Supra 532 Laser System; Quantel Medical, Clermont-Ferrand, France). The micropulse laser settings, were as follows: 300 µm spot size diameter, 1000 mW power, and 300 ms duration with 15% duty cycle.

All MLT procedures were performed by a single surgeon. After a drop of topical anesthetic (Proximetacaine 0.5% ), the patient was seated at the slit lamp and a laser antireflective coated Goldmann three-mirror lens (Ocular Instruments, Bellevue, WA, USA) was placed on the eye to be treated. The laser was focused on the anterior trabecular meshwork and confluent applications were administered over 360º. Since no visible laser induced tissue change endpoint is produced at the TM, we relied on the surgeon’s judgment and skill, resulting in a variable number of confluent and even overlapping spots. The total number of laser applications delivered to each eye was recorded after each treatment. Immediately after the treatment, diclofenac 0.1% eye drops were administered and continued three times daily for five days. The patients were maintained on their pre-treatment drug regimen because most of the patients had advanced optic nerve damage. Patients received a single MLT treatment and no retreatment was done. In patients with previous surgery, the procedure was done sparing the tube shunt or the trabeculectomy area.

Statistics

Central tendency and dispersion values were determined for quantitative variables, as well as absolute and relative frequencies for categorical variables. The post-treatment values were compared with the baseline values using the Wilcoxon signed-rank test with significance corresponding to a p-value of <0.05. The Spearman rank correlation coefficient was used to assess the relationship between baseline IOP and the percent reduction on the last follow up. Data were collected in a retrospective fashion from chart reviews and were analyzed using Stata® version 14 (StataCorp. 2015, Stata Statistical Software: Release 14. College Station, Texas, US: StataCorp LP.)

RESULTS

The baseline demographic characteristics are listed in Table 1. In all, 30 eyes were evaluated in the study. The mean age of the patients was 70 years, with a female/male ratio of 3:1. The average pretreatment cup-disc ratio was 0.85, 86.7 % of the patients were on medications, 26.7 % (n=8) of patients has previous glaucoma surgery and 76.7% of patients were phakic. From the eyes that had previous glaucoma surgery only 4 (50%) were off medications. The mean follow-up period was 19 months (SD ± 10) with a maximum follow-up of 36 months (Table 1).

Table 1
Baseline demographic characteristics (n =30)

Characteristics	Mean	SD
Age (years)	70.20	± 10.5
Cup/Disc ratio	0.85	± 0.12
Follow up (months)	19.00	± 10
	n	%
Sex
Female	22	73.3
Male	8	26.7
Previous Glaucoma surgery
None	22	73.3
Trabeculectomy	6	20.0
Drainage device	2	6.7
Number of glaucoma medication
0	4	13.3
1 drop	8	26.7
2 drops	8	26.7
3 drops	6	20.0
4 drops	4	13.3
Lens status
Phakic	23	76.7
Pseudophakic	7	23.3

An average of 120 burns was applied per session. The mean pre laser IOP was 15.6 mmHg (SD± 3.5) and the post-laser IOP at 1 day, 1 week, 1 month, 3 months, 6 months and in the last follow up, was 14.0, 14.7, 14.9, 15.2, 14.4 and 12.8 mmHg respectively (Figure 1). The average absolute reduction in IOP at the first day, 3 months, and last follow up was 1.60, 1.1 and 1.2 mmHg respectively (Table 2). Thus, post laser immediate drop (at the first day) has a median of 2.00 mmHg and was statistical significant (CI -3.00 - 0, P,0.0012) (Table 3). At first day, the IOP was reduced by 10.3% and in the last follow up was 17.9 %. Table 4 shows the distribution of the percentage of eyes with IOP reduction > 20%, and < 20% through the entire follow up. 30 % (N= 9) of the eyes had an IOP reduction >20% at the first day and 41% (n= 7) in the last control (Figure 2). Some patients were lost in the follow-up. Additionally, there was a trend towards greater IOP reduction with higher base line IOP but this was not statistically significant due to the small sample and design of the study. (Figure 3)

Figure 1
Mean intraocular pressure (IOP) at various time points up to the last follow up

Table 2
Mean intraocular pressure (IOP) with standard deviation and mean IOP reduction from baseline at various time points up to the last follow up

	Baseline N = 30	1 day N = 30	1 week N = 26	1 month N = 22	3 months N =20	6 months N = 20	Last follow up N = 17
Mean IOP (mm Hg)	15.6	14	14.7	14.9	15.2	14.4	12.8
Standard Deviation	± 3.5	± 3.2	± 3.5	± 4.9	± 5.3	± 3.2	± 2.6
Min - Max	10 - 25	9 - 22	10 - 24	10 - 30	10 - 30	11 - 24	08 - 20
IQR	(13-17)	(12-16)	(12-16)	(12-15)	(12-16)	(12-16)	(12-14)
Mean IOP reduction %		10.2	5.7	4.4	2.5	7.7	17.9

• IQR: interquartile range

Table 3
IOP reduction from baseline (median and IQR) at various time points up to the last follow up and P value

IOP Reduction	Median	IQR	p-value*
1 day (mmHg)	-2.00	(-3 a 0)	0.001
1 week (mmHg)	-1	(-3 a 1)	0.0997
1 months (mmHg)	-1	(-3 a 0)	0.0263
3 months (mmHg)	-2	(-3 a 1)	0.3191
6 months (mmHg)	0.5	(-1,5 a 2)	0.986
Last follow up (mmHg)	-2	(-3 a 1)	0.1106

• ^*
  Wilcoxon signed rank test, IQR: interquartile range

Table 4
Distribution of the percentage of eyes with IOP reduction >20%, and < 20% through the entire follow up

		IOP Reduction % *
Follow up	n	>=20%	<20%
1 day	30	9 (30)	21 (70)
1 week	26	7 (27)	19 (73)
1 month	22	6 (27)	16 (73)
3 months	20	7 (35)	13 (65)
6 months	20	2 (10)	18 (90)
Last follow up	17	7 (41)	10 (59)

Figure 2
Percentage of eyes with intraocular pressure (IOP) reduction > 20% from baseline

Figure 3
Baseline IOP and Percentage of reduction

The patients were maintained on their pre-treatment drug regimen and no changes were applied in their medications. None of the patients had significant inflammatory reaction that was documented at the next follow-up. There were no pressure spikes. At the last follow-up no patient had peripheral anterior synechiae. Visual acuity were unchanged in all eyes. There was no statistically significant difference in IOP reduction between groups (age, cup to disc ratio, phakic state, number of medications, previous glaucoma surgery)

DISCUSSION

MLT does not result in any cellular destruction, scarring, or collateral damage because it uses a pulsed laser treatment (15% duty cycle) rather than a continuous laser wave (100% duty cycle) into the trabeculum.⁽²⁴⁾ Despite the few data demonstrating the safety and potential that MLT has to decrease the IOP, its use is still debatable.

The mean drop in IOP was 17.9 % in the last follow up and is lower than that obtained in previous studies, Ingvoldstad et al. ⁽¹⁷⁾ and Detry-Morel et al.⁽²⁶⁾, reported IOP reductions of 18.3% and 12.2 % respectively with MDLT in three months. Gossage et al. ⁽¹⁸⁾ obtained a drop of 18% in IOP at 4 months. Fea et al.⁽²⁰⁾ carried out MDLT in a cohort of 20 patients, with a follow up time of 12 months, they achieve an IOP reduction of 21.3% and ten of the 15 eyes (66.7%) had an IOP reduction >20% in comparison with other studies that only 35.7% of patients achieved such a reduction.⁽²⁶⁾ Others like Lee et al.⁽²⁷⁾ had an IOP reduction of 19.5% at 6 months with an IOP reduction higher than 20% at the first month of 72.9% (n=35) of the patients. Unlike other studies, we only achieved an IOP reduction higher than 20% in 35% (n=7) at three months and 41% (n=7) at the last follow up. In a retrospective case series carried out by Babaloba⁽²⁸⁾ the average drop in IOP was 17.2% and was sustained trough time with a mean follow up of 5 months.

Additionally we found a trend towards greater IOP reduction with higher base line IOP but this was not statistically significant due to the small sample and design of the study; at least 29 patients would be needed in the last control to have a statistically significant result, considering a moderate lineal correlation (r=0.5), with a 95% of confidence level and 80 % of power which means no loss to follow-up. This finding is correlated with several studies that evaluated the predictive factors for success with SLT. ^(29,30) Unlike other studies, we did not observe significant inflammatory response.^(20,26)

One major limitation of this study is the absence of a comparison group, to standard SLT or medical treatment, other several limitations were, a small number of patients, retrospective nature, not all patients were examined at specific time intervals, there was a considerable loss of the number of patients through the follow up. 26.7% of the patients had a previous glaucoma surgery and most of the patients were on topical medical treatment, so there are many confounding effects.

Randomized clinical trials are needed to compare MLT with current IOP-lowering laser therapies, or antiglaucoma medications. The effect may not be long lasting in all cases, and some patients will not respond to the therapy. It is, however, repeatable because damage to the trabeculum is minimal.

In our opinion subthreshold micropulse laser device can also be used for other ophthalmic applications, thus reducing the economic burden of treatment.

CONCLUSION

MLT can temporarily be effective as an adjunct conservative treatment in order to decrease the IOP in some patients with uncontrolled OAG and appears to be safe.

• The abstract of this paper was presented at the 33rd Pan American Congress held in Lima, Peru, as a Free Paper presentation. The actual paper, however, has never been published.

REFERENCES

• ¹ Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96(5):614-8.
• ² Resnikoff S, Pascolini D, Etya’ále D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-51.
• ³ Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7.
• ⁴ Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: proyecto VER. Arch Ophthalmol. 2001;119(12):1819-26.
• ⁵ Campos B, Cerrate A, Montjoy E, Dulanto Gomero V, Gonzales C, Tecse A, et al. (National survey on the prevalence and causes of blindness in Peru). Rev Panam Salud Publica. 2014;36(5):283-9. Spanish.
• ⁶ Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979;97(2):319-22.
• ⁷ Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60(4):359-71.
• ⁸ Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998;105(11):2082-8.
• ⁹ Latina MA, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol. 2002;13(2):94-6.
• ¹⁰ Bovell AM, Damji KF, Hodge WG, Rock WJ, Buhrmann RR, Pan YI. Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty? Can J Ophthalmol. 2011;46(5):408-13.
• ¹¹ Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108(4):773-9.
• ¹² Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998;105(11):2082-8; discussion 2089-90.
• ¹³ Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol. 2003;121(7):957-60.
• ¹⁴ Wong MO, Lee JW, Choy BN, Chan JC, Lai JS. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. 2015;60(1):36-50.
• ¹⁵ Frezzotti P, Motolese I, Peruzzi S et al. Selective Laser Trabeculoplasty: Hypotensive Efficacy, Anterior Chamber Inflammation and Postoperative Pain. Siena, Italy: Department of Surgery, Ophthalmology Unit, University of Siena; 2015.
• ¹⁶ Sayin N, Alkin Z, Ozkaya A, Demir A, Yazici AT, Bozkurt E et al. Efficacy of selective laser trabeculoplasty in medically uncontrolled glaucoma (Article ID 975281). ISRN Ophthalmol. 2013;2013:975281.
• ¹⁷ Ingvoldstad DD, Krishna R, Willoughby L. Micropulse diode laser trabeculoplasty versus argon laser trabeculoplasty in the treatment of open angle glaucoma (abstract). Invest Ophthalmol Vis Sci. 2005;46:123.
• ¹⁸ Gossage DD. 532 nm MicroPulse Laser Trabeculoplasty Successfully Lowers IOP as Primary Treatment. Iridex Clinical Case Reports Series (Internet). (cited 2014 May 7) Available from: http://www.iridex.com/portals/0/physicianeducation/pdf/Gossage%20532%20MLT%202012.pdf
  » http://www.iridex.com/portals/0/physicianeducation/pdf/Gossage%20532%20MLT%202012.pdf
• ¹⁹ Belyea D. Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma (MLT versus SLT) (Internet). (cited 2014vMay 6).Available from: http://clinicaltrials.gov/ct2/show/NCT01956942
  » http://clinicaltrials.gov/ct2/show/NCT01956942
• ²⁰ Fea AM, Bosone A, Rolle T, Brogliatti B, Grignolo FM. Micropulse diode laser trabeculoplasty (MDLT): A phase II clinical study with 12 months follow-up. Clin Ophthalmol. 2008;2(2):247-52.
• ²¹ Luttrull JK, Sramek C, Palanker D, Spink CJ, Musch DC. Long-term safety, high-resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina. 2012;32(2):375-86.
• ²² Lavinsky D, Cardillo JA, Melo LA Jr, Dare A, Farah ME, Belfort R Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(7):4314-23.
• ²³ Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012;26(2):307-14.
• ²⁴ Fudemberg SJ, Myers JS, Katz LJ et al. Trabecular meshwork tissue examination with scanning electron microscopy: a comparison of MicroPulse diode laser (MLT), selective laser (SLT), and argon laser (ALT) trabeculoplasty in human cadaver tissue. Invest Ophthalmol Vis Sci. 2008;49(5):1236.
• ²⁵ Ogata N, Tombran-Tink J, Jo N, Mrazek D, Matsumura M. Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am J Ophthalmol. 2001;132(3):427-9.
• ²⁶ Detry-Morel M, Muschart F, Pourjavan S. Micropulse diode laser (810 nm) versus argon laser trabeculoplasty in the treatment of open-angle glaucoma: comparative short-term safety and efficacy profile. Bull Soc Belge Ophtalmol. 2008;(308):21-8.
• ²⁷ Lee JW, Yau GS, Yick DW, Yuen CY. MicroPulse Laser Trabeculoplasty for the Treatment of Open-Angle Glaucoma. Medicine (Baltimore). 2015;94(49):e2075.
• ²⁸ Babalola OE. Micropulse diode laser trabeculoplasty in Nigerian patients. Clin Ophthalmol. 2015;9:1347-51.
• ²⁹ Hodge WG, Damji KF, Rock W, Buhrmann R, Bovell AM, Pan Y. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol. 2005;89(9):1157-60.
• ³⁰ Ayala M, Chen E. Predictive factors of success in selective laser trabeculoplasty (SLT) treatment. Clin Ophthalmol. 2011;5:573-6.

Publication Dates

• Publication in this collection
  Jul-Aug 2018

History

• Received
  28 Nov 2017
• Accepted
  29 Apr 2018